[VIEW] agent=Privacy & Data Governance Officer | scenario_id=111 | rounds=20

--- Round 0 ---
[R0.1] Privacy & Data Governance Officer (speak, public): Let's start by discussing the Remote Patient Monitoring program for heart failure and COPD. Can you both give me a brief overview of how the program currently operates and what outcomes leadership is expecting?
[R0.2] Care Transitions Program Manager (speak, public): The Remote Patient Monitoring program for heart failure and COPD is currently operating with 180 patients enrolled across 2 hospitals. We've seen a reduction in 30-day readmissions from 21% to 15%. The care team manages around 12 alerts per day with a 2-hour escalation SLA. We're projecting 280 eligible discharges per month with an expected opt-in rate of 45%, with a condition mix of 160 HF and 120 COPD patients per month.
[R0.3] Payer Contracting & Finance Director (speak, public): From a financial perspective, we're projecting an average RPM reimbursement of $120 per member-month with 2 billable months per enrollee. We're also looking at avoiding readmissions, modeled at 38 per quarter, with a variable cost of $6,200 per readmission. The total year-1 program cost is around $920,000, driven mainly by staffing costs of $540,000 and device/shipping costs of $260,000. We're currently at risk for a $1.4M HRRP penalty with a readmission index of 1.08.

--- Round 1 ---
[R1.1] Privacy & Data Governance Officer (speak, public): To better understand the governance implications, can you share more about what specific outcomes leadership is expecting from this RPM program? Additionally, I'd like to share some details on our data governance framework.
[R1.2] Care Transitions Program Manager (speak, public): To operationalize the program safely at scale, we need to finalize the guardrails that will shape patient enrollment. I'd also like to understand how our vendor is handling sensitive patient information. Has there been any recent governance escalation that could impact our rollout timeline?
[R1.3] Payer Contracting & Finance Director (speak, public): To assess operational feasibility, can you share any concerns about workforce coverage or potential operational fragility in managing the increased patient load? Also, have there been any prior data mishaps or governance issues with the vendor that we should be aware of?

--- Round 2 ---
[R2.1] Privacy & Data Governance Officer (speak, public): To address the concerns about workforce coverage and operational fragility, I can share that we've implemented a data governance framework that includes guardrails for patient enrollment and PHI transmission controls. For example, we require TLS 1.2+ for data transmission and AES-256 at rest. We're also minimizing the data elements shared in the vitals feed to just 5 key elements per reading. On the vendor front, while I can't disclose specific incidents, I can share that our third-party security assessment of the vendor scored 83 out of 100 with 2 high findings that are being addressed. Regarding leadership expectations, can you clarify what specific outcomes are being targeted?
[R2.2] Care Transitions Program Manager (speak, public): To address the concerns about specific outcomes leadership is expecting, we're primarily looking at reducing 30-day readmissions and improving patient outcomes for heart failure and COPD patients. We've seen a positive signal in our pilot with readmissions dropping from 21% to 15%. However, to operationalize this safely at scale, we still need clarity on any recent governance escalations that could impact our timeline and any behind-the-scenes payer constraints that might add documentation or measurement burden.
[R2.3] Payer Contracting & Finance Director (leave, public): 

--- Round 3 ---
[R3.1] Privacy & Data Governance Officer (speak, public): To better understand the operational feasibility and potential behind-the-scenes payer constraints, can you share any concerns about workforce coverage or operational fragility in managing the increased patient load? Additionally, I'd like to provide an update on our data processing agreement status with the vendor.
[R3.2] Care Transitions Program Manager (speak, public): To address the concerns about workforce coverage and operational fragility, I can share that our current staffing model is based on a caseload of 55 active patients per RN, with weekend coverage handled by 1 RN per day. We're also managing device logistics with a kit turnaround time of 2.5 days and a loss rate of 3%. Regarding recent governance escalations, I'd like to know if there have been any issues that could impact our rollout timeline.
[R3.3] Payer Contracting & Finance Director (leave, public): 

--- Round 4 ---
[R4.1] Privacy & Data Governance Officer (speak, public): To help us move forward with the expansion decision, can you share any behind-the-scenes payer constraints that might impact our data flows or reporting requirements? Additionally, I'd like to share some information about our data processing agreement status with the vendor.
[R4.2] Care Transitions Program Manager (speak, public): To address the concerns about behind-the-scenes payer constraints, I can share that we've identified some constraints related to documentation and measurement burden that might impact our data flows or reporting requirements. Specifically, we've noted that payers may require additional documentation for certain patient outcomes, which could add to our administrative burden. Regarding recent governance escalations, I haven't been made aware of any specific issues that could directly impact our rollout timeline, but I'd like to confirm if there have been any updates on this front.
[R4.3] Payer Contracting & Finance Director (leave, public): 

--- Round 5 ---
[R5.1] Privacy & Data Governance Officer (leave, public): 
[R5.2] Care Transitions Program Manager (leave, public): 
[R5.3] Payer Contracting & Finance Director (leave, public): 

--- Round 6 ---
[R6.1] Privacy & Data Governance Officer (leave, public): 
[R6.2] Care Transitions Program Manager (leave, public): 
[R6.3] Payer Contracting & Finance Director (leave, public): 

--- Round 7 ---
[R7.1] Privacy & Data Governance Officer (leave, public): 
[R7.2] Care Transitions Program Manager (leave, public): 
[R7.3] Payer Contracting & Finance Director (leave, public): 

--- Round 8 ---
[R8.1] Privacy & Data Governance Officer (leave, public): 
[R8.2] Care Transitions Program Manager (leave, public): 
[R8.3] Payer Contracting & Finance Director (leave, public): 

--- Round 9 ---
[R9.1] Privacy & Data Governance Officer (leave, public): 
[R9.2] Care Transitions Program Manager (leave, public): 
[R9.3] Payer Contracting & Finance Director (leave, public): 

--- Round 10 ---
[R10.1] Privacy & Data Governance Officer (leave, public): 
[R10.2] Care Transitions Program Manager (leave, public): 
[R10.3] Payer Contracting & Finance Director (leave, public): 

--- Round 11 ---
[R11.1] Privacy & Data Governance Officer (leave, public): 
[R11.2] Care Transitions Program Manager (leave, public): 
[R11.3] Payer Contracting & Finance Director (leave, public): 

--- Round 12 ---
[R12.1] Privacy & Data Governance Officer (leave, public): 
[R12.2] Care Transitions Program Manager (speak, public): To move forward with the expansion decision, I need to confirm if there have been any recent governance escalations that could impact our rollout timeline. Additionally, I'd like to understand if there are any updates on behind-the-scenes payer constraints that might force additional documentation or measurement burden.
[R12.3] Payer Contracting & Finance Director (leave, public): 

--- Round 13 ---
[R13.1] Privacy & Data Governance Officer (speak, private to=Care Transitions Program Manager): To address your concerns about recent governance escalations and behind-the-scenes payer constraints, I can share that our data processing agreement with the vendor is nearing completion, with 9 out of 12 sections finalized. We've also established a breach notice requirement within 48 hours and data deletion within 30 days. Regarding payer constraints, while I don't have new information, our previous discussions have highlighted the need for additional documentation for certain patient outcomes. Let's focus on finalizing the expansion decision based on the current information.
[R13.2] Care Transitions Program Manager (leave, public): 
[R13.3] Payer Contracting & Finance Director (leave, public): 

--- Round 14 ---
[R14.1] Privacy & Data Governance Officer (leave, public): 
[R14.2] Care Transitions Program Manager (leave, public): 
[R14.3] Payer Contracting & Finance Director (leave, public): 

--- Round 15 ---
[R15.1] Privacy & Data Governance Officer (leave, public): 
[R15.2] Care Transitions Program Manager (leave, public): 
[R15.3] Payer Contracting & Finance Director (leave, public): 

--- Round 16 ---
[R16.1] Privacy & Data Governance Officer (leave, public): 
[R16.2] Care Transitions Program Manager (leave, public): 
[R16.3] Payer Contracting & Finance Director (leave, public): 

--- Round 17 ---
[R17.1] Privacy & Data Governance Officer (leave, public): 
[R17.2] Care Transitions Program Manager (leave, public): 
[R17.3] Payer Contracting & Finance Director (leave, public): 

--- Round 18 ---
[R18.1] Privacy & Data Governance Officer (leave, public): 
[R18.2] Care Transitions Program Manager (leave, public): 
[R18.3] Payer Contracting & Finance Director (leave, public): 

--- Round 19 ---
[R19.1] Privacy & Data Governance Officer (leave, public): 
[R19.2] Care Transitions Program Manager (leave, public): 
[R19.3] Payer Contracting & Finance Director (leave, public): 

